Lucid, Inc., doing business as Caliber Imaging & Diagnostics, Inc., is a medical technologies company that designs, develops and markets imaging solutions that shows tissue at the cellular level. The Company offers in-vivo confocal microscopes designed for imaging skin and other tissue. The Company is engaged in development of VivaScope, a suite of imaging products. Its telepathology system allows near real-time collaboration with remote specialists. Its RS-G4 Upright Research Confocal Microscope is used to locate a data collection area on a large specimen, such as a whole brain section. Its specialty confocal microscopes include VivaScope 3000, which is capable of imaging cells in the epidermis of skin and the fibrous tissue, primarily collagen and fibrin, in the dermis, and VivaScope 1500, which provides non-invasive, in vivo images of the epithelium and supporting stroma. Its clinical solutions include VivaScope 1500, VivaScope 3000, VivaNet and VivaScan.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Symbol: OTCMKTS:LCDX
- CUSIP: N/A
- Web: www.caliberid.com/
Capitalization:- Market Cap: $9.22 million
- Outstanding Shares: 8,384,000
Average Prices:- 50 Day Moving Avg: $1.07
- 200 Day Moving Avg: $1.11
- 52 Week Range: $0.40 - $1.60
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.14 million
- Price / Sales: 2.94
- Book Value: ($1.69) per share
- Price / Book: -0.65
Profitability:- EBIDTA: ($5,460,000.00)
- Net Margins: -212.49%
- Return on Assets: -316.57%
Misc:- Average Volume: 4,919 shs.
Frequently Asked Questions for Lucid (OTCMKTS:LCDX)
What is Lucid's stock symbol?
Lucid trades on the OTCMKTS under the ticker symbol "LCDX."
Who are some of Lucid's key competitors?
Some companies that are related to Lucid include Oxford Pharmascience Group Plc (OXP), Anthera Pharmaceuticals (ANTH), Innovus Pharmaceuticals (INNV), Advanced Oncotherapy PLC (AVO), Xtant Medical Holdings (XTNT), Soligenix (SNGX), Concepta PLC (CPT), Evgen Pharma PLC (EVG), Proteome Sciences plc (PRM), Synairgen plc (SNG), Ampliphi Biosciences Corp (APHB), Ixico Plc (IXI), Akers Biosciences (AKR), Achieve Life Sciences (ACHV), InspireMD (NSPR), ValiRx Plc (VAL), 3SBio (SSRX) and Acer Therapeutics (ACER).
Who are Lucid's key executives?
Lucid's management team includes the folowing people:
- William J. Shea, Chairman of the Board
- L. Michael Hone, Chief Executive Officer, Director
- Richard C. Christopher, Chief Financial Officer
- Jay M. Eastman Ph.D., Chief Science Officer
- William J. Fox, Vice President - Technology Operations, Chief Technology Officer
- Richard N. Stathes, Vice President of Sales and Marketing
- Joseph R. Williams, Vice President - Global Marketing
- Frank Mentesana, Vice President - Manufacturing
- Karen A. Long, Controller
- William F. O'Dell, Director
How do I buy Lucid stock?
Shares of Lucid can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lucid's stock price today?
One share of Lucid stock can currently be purchased for approximately $1.10.
MarketBeat Community Rating for Lucid (OTCMKTS LCDX)MarketBeat's community ratings are surveys of what our community members think about Lucid and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Lucid (OTCMKTS:LCDX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Lucid (OTCMKTS:LCDX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Lucid (OTCMKTS:LCDX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Lucid (OTCMKTS:LCDX)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Lucid (OTCMKTS:LCDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lucid (OTCMKTS:LCDX)Insider Trades by Quarter for Lucid (OTCMKTS:LCDX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/31/2014 | Northeast Lcd Capital, Llc | Major Shareholder | Buy | 24,468,808 | $0.55 | $13,457,844.40 |  |
| 7/31/2014 | Paul Stuka | Director | Buy | 1,101,230 | $0.55 | $605,676.50 | |
| 6/5/2014 | L. Michael Hone | CEO | Buy | 200,000 | $1.00 | $200,000.00 | |
| 12/3/2013 | Kevin M Cronin | Director | Buy | 21,000 | $0.80 | $16,800.00 | |
| 11/18/2013 | Kevin M Cronin | Director | Buy | 4,500 | $1.02 | $4,590.00 | |
| 11/15/2013 | Kevin M Cronin | Director | Buy | 2,000 | $0.95 | $1,900.00 | |
| 8/22/2013 | Kevin M Cronin | Director | Buy | 3,750 | $0.78 | $2,925.00 | |
| 8/20/2013 | Kevin M Cronin | Director | Buy | 5,000 | $1.00 | $5,000.00 | |
| 8/16/2013 | Kevin M Cronin | Director | Buy | 7,500 | $1.00 | $7,500.00 | |
| 8/14/2013 | Kevin M Cronin | Director | Buy | 25,500 | $0.98 | $24,990.00 | |
| 6/14/2013 | Kevin M Cronin | Director | Buy | 6,000 | $0.98 | $5,880.00 | |
| 6/7/2013 | Kevin M Cronin | Director | Buy | 16,750 | $0.80 | $13,400.00 | |
| 12/18/2012 | William J Shea | Director | Buy | 214,286 | $1.40 | $300,000.40 | |
| 11/28/2012 | William J Shea | Director | Buy | 40,000 | $1.39 | $55,600.00 | |
| 11/27/2012 | William J Shea | Director | Buy | 111,000 | $1.41 | $156,510.00 | |
| 11/20/2012 | William J Shea | Director | Buy | 9,000 | $1.50 | $13,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Lucid (OTCMKTS:LCDX)
Latest Headlines for Lucid (OTCMKTS:LCDX)
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Lucid (LCDX) Chart for Sunday, September, 24, 2017
